Cell line name |
SK-MEL-28-VR |
Accession |
CVCL_AP99 |
Resource Identification Initiative |
To cite this cell line use: SK-MEL-28-VR (RRID:CVCL_AP99) |
Comments |
Population: Caucasian. Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032). Derived from site: In situ; Skin; UBERON=UBERON_0002097. Cell type: Melanocyte of skin; CL=CL_1000458. |
Sequence variations |
- Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 3236; EGFR; Simple; p.Pro753Ser (c.2257C>T); ClinVar=VCV000376081; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; 9588; PTEN; Simple; p.Thr167Ala (c.499A>G); ClinVar=VCV001686107; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; 11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Leu145Arg (c.434T>G); ClinVar=VCV001027110; Zygosity=Homozygous (from parent cell line).
|
Disease |
Cutaneous melanoma (NCIt: C3510) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0526 (SK-MEL-28) |
Sex of cell |
Male |
Age at sampling |
51Y |
Category |
Cancer cell line |
Publications | PubMed=26497853; DOI=10.18632/oncotarget.5755; PMCID=PMC4747351 Fofaria N.M., Frederick D.T., Sullivan R.J., Flaherty K.T., Srivastava S.K. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Oncotarget 6:40535-40556(2015) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_AP99
|
Encyclopedic resources |
Wikidata; Q54954017
|
Entry history |
Entry creation | 02-May-2016 |
Last entry update | 05-Oct-2023 |
Version number | 16 |
---|